ArticleCell2014
A monoclonal antibody that targets a NaV1.7 channel voltage sensor for pain and itch relief.
Article in Cell, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 94 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 203 citations in OpenAlex.
- Trigeminal neuralgia: from clinical challenges to molecular insights.The journal of headache and pain · 2026Review
- Discordance between preclinical and clinical testing of Na V 1.7-selective inhibitors for pain.Pain · 2025Review
- Differential expression of slow and fast-repriming tetrodotoxin-sensitive sodium currents in dorsal root ganglion neurons.Frontiers in molecular neuroscience · 2023Article
- Voltage-gated sodium channels in diabetic sensory neuropathy: Function, modulation, and therapeutic potential.Frontiers in cellular neuroscience · 2022Review
- Selective Targeting of Nav1.7 with Engineered Spider Venom-Based Peptides.Channels (Austin, Tex.) · 2021Review
- Review
- Common and discrete mechanisms underlying chronic pain and itch: peripheral and central sensitization.Pflugers Archiv : European journal of physiology · 2021Review
- TLR8 in the Trigeminal Ganglion Contributes to the Maintenance of Trigeminal Neuropathic Pain in Mice.Neuroscience bulletin · 2021Article
- Peripheral Voltage-Gated Cation Channels in Neuropathic Pain and Their Potential as Therapeutic Targets.Frontiers in pain research (Lausanne, Switzerland) · 2021Review
- The Impact of Immunological Checkpoint Inhibitors and Targeted Therapy on Chronic Pruritus in Cancer Patients.Biomedicines · 2020Review
- Neurological Disturbances of Ciguatera Poisoning: Clinical Features and Pathophysiological Basis.Cells · 2020Review
- Advances in Understanding the Initial Steps of Pruritoceptive Itch: How the Itch Hits the Switch.International journal of molecular sciences · 2020Review
- Physiology and Pathophysiology of Itch.Physiological reviews · 2020Review
- Complementary roles of murine NaScientific reports · 2020Article
- Comprehensive engineering of the tarantula venom peptide huwentoxin-IV to inhibit the human voltage-gated sodium channel hNaThe Journal of biological chemistry · 2020Article
- A dual role for peripheral GDNF signaling in nociception and cardiovascular reflexes in the mouse.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- A New Generation of Treatments for Itch.Acta dermato-venereologica · 2020Review
- Voltage-gated Sodium Channels and Blockers: An Overview and Where Will They Go?Current medical science · 2019Review
- 3'-O-Methylorobol Inhibits the Voltage-Gated Sodium Channel Nav1.7 with Anti-Itch Efficacy in A Histamine-Dependent Itch Mouse Model.International journal of molecular sciences · 2019Article
- C-fibers may modulate adjacent Aδ-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system.The journal of headache and pain · 2019Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
- Retraction · 2020-06-25Falsification/Fabrication of Data · Falsification/Fabrication of Results · Investigation by Journal/Publisher · · Jun-Ho Lee named as responsible for fabrication of results;
- Commented on by
- Retracted
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Voltage-gated sodium (NaV) channels control the upstroke of the action potentials in excitable cells. Multiple studies have shown distinct roles of NaV channel subtypes in human physiology and diseases, but subtype-specific therapeutics are lacking and the current efforts have been limited to small molecules. Here, we present a monoclonal antibody that targets the voltage-sensor paddle of NaV1.7, the subtype critical for pain sensation. This antibody not only inhibits NaV1.7 with high selectivity, but also effectively suppresses inflammatory and neuropathic pain in mice. Interestingly, the antibody inhibits acute and chronic itch despite well-documented differences in pain and itch modulation. Using this antibody, we discovered that NaV1.7 plays a key role in spinal cord nociceptive and pruriceptive synaptic transmission. Our studies reveal that NaV1.7 is a target for itch management, and the antibody has therapeutic potential for suppressing pain and itch. Our antibody strategy may have broad applications for voltage-gated cation channels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.